Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care
Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.
Pharma & Biotech
Pharma & Biotech
Otsuka reports VOYXACT preserved kidney function for two years in Phase 3 trial
Otsuka’s two-year VOYXACT data could reshape IgA nephropathy care. See what the eGFR results mean for FDA approval and clinical adoption.
Pharma & Biotech
Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?
Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.
Pharma & Biotech
Why Otsuka’s $1.2bn Transcend Therapeutics buyout could reshape PTSD drug development
Find out how Otsuka’s Transcend Therapeutics acquisition could reshape rapid-acting PTSD treatment development.
Pharma & Biotech
Can Uqora’s Target expansion turn urinary health into a mainstream wellness category?
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.